Hemlibra®
HEMLIBRA® (emicizumab-kxwh) injection, for subcutaneous use is a bispecific factor IXa- and factor X-directed antibody indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors.
For indications, dosing and other information, please refer to the prescribing information.
Fully Accredited Distributor
BDI Pharma is a Verified-Accredited Wholesale Distributor. Always rest assured your product is being handled with the utmost care and professionalism.
For the FDA Wholesale Distributor License Reporting Site, click here.
Contact Us
1-800-948-9834
BDI Pharma, LLC Headquarters
120 Research Drive, Columbia, SC, 29203
120 Research Drive, Columbia, SC, 29203
